Works in Investigational New Drugs, 2023, Vol 41, Issue 3

Results: 20

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 493, doi. 10.1007/s10637-023-01371-6

By:

Falchook, Gerald S;
Sachdev, Jasgit;
Imedio, Esteban Rodrigo;
Kumar, Sanjeev;
Mugundu, Ganesh M;
Jenkins, Suzanne;
Chmielecki, Juliann;
Jones, Suzanne;
Spigel, David R;
Johnson, Melissa

Publication type:

Article

Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 371, doi. 10.1007/s10637-023-01370-7

By:

Alexanian, Arshak R.;
Stoellinger, Heidi Marie;
de Araujo Farias, Virginea;
Quiñones-Hinojosa, Alfredo

Publication type:

Article

Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 532, doi. 10.1007/s10637-023-01363-6

By:

Hu, Shiqi;
Liu, Yaqin;
Yang, Qidong;
Chen, Lin;
Chai, Huizi;
Xiao, Mingzhe;
Qi, Chuang;
Qiu, Wei

Publication type:

Article

Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 483, doi. 10.1007/s10637-023-01362-7

By:

Tamai, Toshiyuki;
Narukawa, Mamoru

Publication type:

Article

Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.

Published in:

2023

By:

Khalil, Danny N.;
González-Albo, Isabel Prieto;
Rosen, Lee;
Lillie, Tom;
Stacey, Andrea;
Parfitt, Lola;
Soff, Gerald A.

Publication type:

Correction Notice

Prospective role of liquid biopsy for early screening in laryngeal cancer.

Published in:

2023

By:

Gong, Xiao-yang;
Chen, Hai-bing;
Lu, Zhao-yi;
Zhu, Chan;
Chen, Dong-sheng;
Chen, Xi

Publication type:

Letter

A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 365, doi. 10.1007/s10637-023-01364-5

By:

Buchbinder, Elizabeth I.;
Giobbie-Hurder, Anita;
Ott, Patrick A.

Publication type:

Article

Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 512, doi. 10.1007/s10637-023-01366-3

By:

Yamamoto, Takafumi;
Mizuno, Kazuyuki;
Ito, Takanori;
Yokoyama, Shinya;
Yamamoto, Kenta;
Imai, Norihiro;
Ishizu, Yoji;
Honda, Takashi;
Ishikawa, Takuya;
Kanamori, Akira;
Yasuda, Satoshi;
Toyoda, Hidenori;
Yokota, Kenji;
Hase, Tetsunari;
Nishio, Naoki;
Maeda, Osamu;
Ishii, Makoto;
Sone, Michihiko;
Ando, Yuichi;
Akiyama, Masashi

Publication type:

Article

Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 522, doi. 10.1007/s10637-023-01367-2

By:

Ma, Li;
Ma, Juan;
Sun, Xin;
Liu, Honggang

Publication type:

Article

Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 438, doi. 10.1007/s10637-023-01360-9

By:

Zhang, Chan;
Zhao, Xinan;
Wang, Zifeng;
Gong, Tao;
Zhao, Hong;
Zhang, Dong;
Niu, Yuhu;
Li, Xiaoning;
Zhao, Xuhua;
Li, Gaopeng;
Dong, Xiushan;
Zhang, Li;
Liu, Chang;
Xu, Jun;
Yu, Baofeng

Publication type:

Article

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 421, doi. 10.1007/s10637-023-01359-2

By:

Dasari, Arvind;
Hamilton, Erika P.;
Falchook, Gerald S.;
Wang, Judy S.;
Li, Daneng;
Sung, Max W.;
Chien, Caly;
Nanda, Shivani;
Tucci, Christopher;
Hahka-Kemppinen, Marjo;
Paulson, Andrew Scott

Publication type:

Article

HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 473, doi. 10.1007/s10637-023-01338-7

By:

Zhu, Xiaoxue;
Ding, Yanhua;
Wang, Qian;
Yang, Guiyu;
Zhou, Liang;
Wang, Qingyu

Publication type:

Article

Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 463, doi. 10.1007/s10637-023-01329-8

By:

Tan, Xueyun;
Wang, Sufei;
Xia, Hui;
Chen, Hebing;
Xu, Juanjuan;
Meng, Daquan;
Wang, Zhihui;
Li, Yan;
Yang, Lian;
Jin, Yang

Publication type:

Article

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 380, doi. 10.1007/s10637-022-01326-3

By:

Stathis, Anastasios;
Tolcher, Anthony W.;
Wang, Judy S.;
Renouf, Daniel J.;
Chen, Lin-Chi;
Suttner, Leah H.;
Freshwater, Tomoko;
Webber, Andrea L.;
Nayak, Tapan;
Siu, Lillian L.

Publication type:

Article

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 391, doi. 10.1007/s10637-023-01357-4

By:

Abuhadra, Nour;
Sun, Ryan;
Bassett Jr, Roland L.;
Huo, Lei;
Chang, Jeffrey T.;
Teshome, Mediget;
Clayborn, Alyson R.;
White, Jason B.;
Ravenberg, Elizabeth E.;
Adrada, Beatriz E.;
Candelaria, Rosalind P.;
Yang, Wei;
Ding, Qingqing;
Symmans, W. Fraser;
Arun, Banu;
Damodaran, Senthil;
Koenig, Kimberly B.;
Layman, Rachel M.;
Lim, Bora;
Litton, Jennifer K.

Publication type:

Article

Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 411, doi. 10.1007/s10637-023-01358-3

By:

Tozuka, Takehiro;
Yanagitani, Noriko;
Yoshida, Hiroshi;
Manabe, Ryo;
Ogusu, Shinsuke;
Tsugitomi, Ryosuke;
Sakamoto, Hiroaki;
Amino, Yoshiaki;
Ariyasu, Ryo;
Uchibori, Ken;
Kitazono, Satoru;
Seike, Masahiro;
Gemma, Akihiko;
Nishio, Makoto

Publication type:

Article

Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 453, doi. 10.1007/s10637-023-01356-5

By:

Li, Xiaoli;
Liu, Yuyan;
Zhu, Minhui;
He, Cuixia;
Xu, Yuanyuan;
Ding, Jiaxiang;
Wang, Ying;
Shan, Rongfang;
Liu, Bingyan;
Ding, Yuzhou;
Xie, Jing;
Zhou, Huan;
Wang, Zhiqiang;
Liu, Yuanyuan

Publication type:

Article

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 503, doi. 10.1007/s10637-023-01351-w

By:

Luo, Yang;
Cheng, Ying;
Wu, Chunjiao;
Ye, Hui;
Chen, Naihan;
Zhang, Fan;
Wei, Hua;
Xu, Binghe

Publication type:

Article

Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 431, doi. 10.1007/s10637-023-01348-5

By:

Jia, Dong-Dong;
Xu, Yu;
Li, Ting;
Yang, Ji-Long;
Chen, Yong;
Li, Tao

Publication type:

Article

Brigatinib pharmacokinetics in patients with chronic hepatic impairment.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 402, doi. 10.1007/s10637-023-01339-6

By:

Hanley, Michael J.;
Kerstein, David;
Tugnait, Meera;
Narasimhan, Narayana;
Marbury, Thomas C.;
Venkatakrishnan, Karthik;
Gupta, Neeraj

Publication type:

Article